Gene Amplification¶

A natural or artificial increase in the copy number of a selected gene or bounded genomic region without a proportional increase in the rest of the genome.

Version: v1 · 2026-09-28 · History
Domain-specific #: 7658
Domain group: Natural Sciences
Origin domain: Biology & Ecology
Subdomain: Genetics → Biology & Ecology
Aliases: Specific Gene Amplification, Target Gene Amplification

Core Idea¶

Gene amplification is an increase in the copy number of a selected gene or bounded genomic region without a proportional increase in other genes.^[1] The relative selectivity is constitutive: an entire genome doubling changes gene dosage but is not ordinarily called amplification of one gene. The resulting repeated segment or laboratory product can be called an amplicon.

The term spans natural biological processes and artificial nucleic-acid methods, but these senses share a controlled invariant: a defined target sequence becomes represented in more copies relative to a broader background. The mechanism, physical form, inheritance, and interpretation must be stated rather than merged.

Natural amplification can be developmentally regulated.^[2] Certain cells generate extra copies of a locus whose product is required in unusually large amounts. Classic work on amphibian oocytes showed selective amplification of ribosomal DNA associated with extrachromosomal nucleoli.^[3] The change was cell-type-specific and reversible across development, demonstrating that differentiated cells can alter the relative abundance of particular DNA sequences without whole-genome duplication.

Amplification can also arise under selection.^[4] A preexisting or newly generated copy-number increase can raise dosage of a gene whose product helps survival under a drug, toxin, nutrient limitation, or other pressure. Cells carrying useful amplifications may expand in the population. Selection favors the phenotype; it does not necessarily direct a specific amplification event to occur.

Bacteria and yeast can amplify loci affecting antimicrobial, drug, or metal resistance. Plants exposed repeatedly to herbicides can acquire or enrich extra copies of a target gene such as EPSPS, producing more target enzyme and reducing the effectiveness of inhibition at the organismal level. The mechanistic route and copy-number structure can differ across lineages.

Cancer genomes frequently contain focal amplifications that increase dosage of growth-promoting genes. Amplified DNA can appear in tandem chromosomal regions, complex rearrangements, or extrachromosomal DNA. Copy number may contribute to oncogene expression and treatment response, but the presence of extra copies does not by itself prove that the amplified gene drives the disease.

Gene amplification overlaps copy-number variation but is not synonymous with every copy-number difference.^[5] Copy-number variation includes deletions and duplications of many sizes and population frequencies. “Amplification” commonly emphasizes a gain, often multiple copies, a target locus, and a biological or experimental process producing that gain.

Gene duplication is a source of additional copies and a major evolutionary process. Over long times, duplicated genes can diverge in function or regulation. Gene amplification often refers to a copy-number state or process at a locus, sometimes unstable and selected in the short term. The categories overlap, but a fixed ancient paralog family is not automatically described as an ongoing amplification.

Aneuploidy changes the copy number of a chromosome, and polyploidy changes whole chromosome sets or genomes. Both can raise the dosage of a gene, but the defining “without proportional increase in other genes” boundary separates focal or regional amplification from broad dosage gain.

Copy number and expression are distinct. Extra copies can increase RNA or protein output, but chromatin state, promoter activity, feedback, transcript stability, and cellular context can weaken or reverse the relationship. A valid account measures or qualifies the expression consequence instead of treating it as definitional.

Likewise, copy number and phenotype are distinct.^[6] A resistance-associated amplification may be sufficient in one background, contingent on other alleles in another, or carry a fitness cost when selection is removed. Association, mechanism, and causal contribution require different evidence.

Artificial amplification produces many copies of a selected nucleic-acid target for detection, quantification, sequencing, cloning, or other analysis. Polymerase chain reaction uses cycles of priming and synthesis; isothermal methods use different enzymes and reaction logics. These are implementations of target amplification, not natural genomic copy-number states.

In a laboratory assay, amplification of the target in the reaction tube does not imply that the source organism had a gene amplification. PCR can make many product molecules from a genome with one copy per haploid set. Conversely, detecting a biological copy-number gain requires a calibrated measurement relative to reference loci and sample composition.

Assays can report relative or absolute copy number using sequencing depth, quantitative PCR, digital PCR, arrays, fluorescence hybridization, or cytogenetic methods. Each has normalization assumptions, resolution, dynamic range, and sensitivity to mosaicism, tumor purity, ploidy, and mapping ambiguity.

An amplicon has contextual meaning. In molecular assays it often means the nucleic-acid product bounded by primers. In cancer genomics it can mean an amplified genomic segment. The shared word should not cause a laboratory product and a biological structural alteration to be treated as the same physical object.

Amplification can be unstable. Repeated regions may contract by recombination, extrachromosomal elements may segregate unevenly, and a costly amplification may decline after selection is relaxed. A measured copy-number state therefore belongs to a sample, cell population, and time.

The structural identity recurs across development, adaptation, cancer, and laboratory analysis, though causal mechanisms differ. All cases declare a bounded target and an increased number of corresponding sequence copies relative to a reference population or background. Removing molecular-genetic typing yields generic Amplification, so the node does not clear the prime bar.

Structural Signature¶

Sig role-phrases:

the bounded sequence target — the gene or delimited DNA or RNA region whose copy number is being tracked.
the reference background — other loci, input molecules, or a genomic baseline against which proportional gain is defined.
the amplification context — the developmental, selected, pathological, evolutionary, or artificial setting that determines what the copies physically mean.
the copy-generating route — replication, recombination, rearrangement, or assay chemistry that produces additional target molecules or segments.
the amplified product — tandem or extrachromosomal genomic copies, a complex amplified region, or a bounded assay amplicon.
the relative copy gain — increased representation of the target without a proportional increase in the surrounding genomic or molecular background.
the copy-number measurement — a calibrated target-to-reference estimate qualified by ploidy, sample mixture, resolution, and assay range.
the consequence chain — the separately tested progression from extra copies to expression, protein abundance, detectability, fitness, or phenotype.
the genomic-scale boundary — the distinction between focal or regional amplification and chromosome-wide aneuploidy or whole-genome polyploidy.
the assay-state boundary — the distinction between copies created inside a laboratory reaction and a copy-number gain already present in the source genome.

What It Is Not¶

Not ordinary whole-genome replication before cell division. Amplification requires a selected gene or bounded region to gain copies relative to a broader genomic or molecular background, not the proportional copying of the entire genome.
Not every duplication or copy-number difference. Ancient paralogs, deletions, single duplications, chromosome gains, aneuploidy, and polyploidy may alter dosage, but they do not all instantiate a focal or regional amplification process.^[7]
Not equivalent to increased expression or protein abundance. Extra copies can affect output, yet chromatin, regulation, transcript stability, and cellular context can decouple copy number from RNA, protein, and phenotype.
Not proof of adaptation, disease causation, or stable inheritance. An amplification may be transient, developmentally regulated, selectively enriched, incidental, or one contributor among many; each stronger claim requires its own evidence.
Not a mutation deliberately produced by selection because it was needed. Selection can increase the frequency of cells or organisms carrying a useful copy-number state without directing the particular amplification event.
Not established in vivo because a laboratory assay made abundant product. PCR and other amplification methods multiply a target in a reaction tube, so biological gene amplification requires a calibrated copy-number comparison to reference loci and sample composition.
Not one undifferentiated amplicon meaning. The term can denote an amplified genomic segment or an assay product; interpretation must state the natural or artificial process and the physical material at issue.

Scope of Application¶

Gene amplification spans natural genomic change and artificial nucleic-acid copying, but every literal habitat must preserve a bounded sequence target and an explicit background against which its relative copy gain is measured. Reports must distinguish copies present in a source genome from copies produced in an assay and must not infer expression, phenotype, or causation from copy number alone.^[8]

Developmental genetics. Regulated cell types can selectively increase a locus, as in amplified ribosomal DNA, when the gain is established relative to bulk genomic DNA rather than by whole-genome replication.
Microbial and yeast adaptation. Amplification of resistance, target, efflux, or detoxification genes can be tracked under drug, antimicrobial, metal, or nutrient selection, with generation of the gain kept distinct from selection of copy-bearing cells.
Plant herbicide resistance. Target-gene copy gains such as amplified EPSPS belong when calibrated genomic measurements connect the bounded locus to the selected population and separate dosage from enzyme response and survival.
Cancer genomics. Focal, tandem, rearranged, or extrachromosomal oncogene amplifications are literal instances, while driver status, expression consequence, and treatment effect require additional evidence.
Molecular evolution and copy-number dynamics. Short-term regional gains, contractions, and selected amplifications can be studied alongside duplication processes, provided ancient paralog families, chromosome gains, aneuploidy, and polyploidy are not automatically relabeled as focal amplification.
Genomic diagnostics and copy-number analysis. Sequencing depth, arrays, quantitative or digital PCR, hybridization, and cytogenetic assays estimate target-to-reference gain under declared ploidy, purity, mosaicism, resolution, and dynamic-range assumptions.
Laboratory target amplification. PCR, ligase chain reaction, transcription-mediated amplification, and rolling-circle amplification create bounded DNA or RNA products for detection, quantification, sequencing, or cloning; this assay habitat does not imply that the source organism carried a genomic amplification.

Clarity¶

Naming gene amplification makes “more gene” a testable copy-number claim rather than an ambiguous report of stronger expression, a larger assay signal, or a general increase in DNA. It separates focal or bounded sequence gain from whole-chromosome or whole-genome dosage changes, and it keeps the copy-number state distinct from its possible consequences for RNA, protein, phenotype, or fitness. Those downstream effects require their own evidence.

The term also prevents laboratory amplification from being mistaken for a property of the source genome: an abundant PCR product may have been generated from a single-copy locus, while a biological amplification must be measured against reference loci and interpreted in light of ploidy and sample composition. The sharper question is: which sequence gained copies relative to which genomic or assay baseline, in what cells or reaction, and what measurement distinguishes that gain from expression change, broad dosage change, or amplification introduced by the assay itself?

Manages Complexity¶

Gene amplification compresses a heterogeneous set of genomic structures and assay products into a relative-copy-number description: a bounded target sequence, a reference background, the number and physical arrangement of added copies, the cells or reaction in which they occur, and the time at which they are measured. Those variables separate the principal regimes without conflating them. A focal genomic gain can be developmental, selected, pathological, or evolutionarily retained; a laboratory amplicon can instead be produced from an unamplified source genome. Tracking target-to-reference copy number also distinguishes amplification from chromosome gain or whole-genome duplication and makes tandem repeats, complex rearrangements, and extrachromosomal copies comparable at the level of dosage.

The concept further orders a long causal chain into stages: generation of extra copies, survival or selection of copy-bearing cells, transcriptional or protein output, and phenotypic consequence. Evidence can then support copy gain while leaving expression or causation unresolved, or show that a useful amplification contracts after selection is relaxed. The compression stops at the copy-number state: ploidy, mosaicism, sample purity, mapping ambiguity, chromatin regulation, fitness background, and assay normalization determine what the estimate means. It therefore cannot turn abundant PCR product into evidence of an in-vivo gain, nor an amplified locus into proof that its gene drives a phenotype.

Abstract Reasoning¶

The first diagnostic move is from a calibrated target-to-reference measurement to a claim about biological copy-number gain. The analyst asks whether the target signal exceeds appropriate reference loci, then conditions that inference on ploidy, sample mixture, mosaicism, mapping ambiguity, assay range, and the physical scale of the gain. A high target signal supports focal or regional amplification only when chromosome-wide dosage and copies generated inside the assay have been excluded. Thus abundant PCR product is evidence that the reaction amplified its target, not by itself that the source genome contained extra target copies.

Causal reasoning proceeds through an ordered chain rather than jumping from copy number to phenotype. Evidence may show that extra copies were generated, that copy-bearing cells became enriched under selection, that RNA or protein output changed, and that the change contributed to resistance, growth, or another phenotype. Support for one link does not establish the next. Comparing copy number and expression across cells, conditions, or time points can therefore distinguish dosage without output from output without a demonstrated phenotypic effect.

Interventionist and regime reasoning then asks what should change when the relevant pressure or context changes. If a costly amplification is maintained because it is advantageous under a drug or herbicide, imposing that pressure predicts enrichment of copy-bearing cells, while relaxing it may permit contraction or loss; neither result implies that selection directed the original amplification event. Developmentally programmed, tumor-associated, selected, and artificial amplification must be interpreted under their own mechanisms. The conclusion should consequently be graded: a bounded gain may be established while its origin, stability, expression consequence, and causal importance remain unresolved.

Knowledge Transfer¶

Within genetics and molecular biology, gene amplification transfers literally across developmental regulation, microbial and plant adaptation, cancer genomics, copy-number analysis, and laboratory nucleic-acid methods when a bounded target sequence gains copies relative to an explicit background. The shared cargo is the target–reference relation, the distinction between generation and selection of extra copies, and the separation of copy number from expression and phenotype. The same diagnostic asks which sequence increased relative to which loci or input baseline; the same interventions alter selective pressure, reaction chemistry, or measurement design; and the same vocabulary of focal gain, amplicon, ploidy, mosaicism, and assay normalization remains operational, provided natural genomic states and assay products are kept distinct.

Beyond molecular genetics, the honest transfer is (B) shared abstract mechanism with an (A) analogy boundary. The parent Amplification captures selective increase of one component or signal relative to a background, and the caution against confusing amplified measurement output with source abundance can inform other measurement systems. What remains home-bound is the literal genetic machinery: genes and loci, DNA or RNA copies, chromosomes, aneuploidy and polyploidy, recombination or replication routes, and molecular copy-number assays. A stronger signal in electronics, communication, or social diffusion may instantiate Amplification, but it is not gene amplification; likening repeated documents or messages to an amplicon is analogy only. The stopping boundary is loss of a nucleic-acid target and genomic or assay copy-number reference, after which the transferable lesson belongs to the parent rather than this node.

Examples¶

Canonical¶

Brown and Dawid's 1968 work on amphibian oocytes provides a defining natural case.^[9] They found extra copies of the ribosomal-DNA region associated with extrachromosomal nucleoli in the oocyte germinal vesicle.^[10] The ribosomal sequence was enriched relative both to bulk nuclear DNA and to DNA homologous to other RNA classes, so the observation was not a proportional duplication of the whole genome.^[11] Its cell-type-specific and reversible developmental pattern further distinguished the state from an ancient fixed gene family. The result established that a differentiated cell can selectively increase a bounded locus during development. It did not make expression or ribosome output part of the definition: those are downstream consequences to be measured separately from the copy-number gain itself.

Mapped back: Ribosomal DNA is the bounded sequence target, while bulk nuclear DNA and the comparison loci supply the reference background. Oocyte development supplies the amplification context, and the extrachromosomal copies are the amplified product demonstrating the relative copy gain. The target-to-background comparison is the copy-number measurement, and the absence of whole-genome multiplication preserves the genomic-scale boundary.

Applied / In Practice¶

Laboratory target amplification supplies a distinct and commonly used molecular practice. In a PCR assay, primers bound a selected DNA fragment and repeated synthesis creates many molecules of that fragment so it can be detected or analyzed. The reaction may begin with a source genome containing only its ordinary locus copy; abundant product at the end therefore establishes amplification in the tube, not a biological copy-number gain in the organism. A copy-number study must add calibrated reference loci and account for sample composition and ploidy before making that stronger claim. The physical product is an amplicon in the assay sense, even though it is not a tandem or extrachromosomal amplified region in the source genome. This example shows why the shared word names a relative-copy operation but does not erase the distinction between artificial product and genomic state.

Mapped back: The primer-bounded fragment is the bounded sequence target, the input template or reference locus is the reference background, and PCR chemistry is the copy-generating route within the amplification context. The reaction product is the amplified product displaying the relative copy gain. Refusing to infer an in-vivo state from that product enforces the assay-state boundary; calibrated genomic comparison would require the copy-number measurement.

Structural Tensions¶

T1: Copy-number gain versus increased output. Extra copies can raise RNA or protein abundance, but regulation, chromatin state, feedback, and cellular context can interrupt that progression. Treating expression as definitional makes the copy-number claim stronger than its measurement, while ignoring output can miss why the gain matters.

Diagnostic: Which evidence establishes the target-to-reference copy gain, and which separate evidence connects it to expression or protein abundance?

T2: Amplification generation versus selective enrichment. A copy-number change may arise before a pressure is applied, while selection changes the frequency of cells or organisms carrying it. Collapsing these stages invites a directed-change account; separating them too rigidly can obscure the population dynamics through which the amplification becomes prominent.

Diagnostic: Do the observations identify when new copies arose, when copy-bearing lineages expanded, or only the final enriched state?

T3: Focal selectivity versus broad dosage change. Gene amplification requires a bounded target to increase relative to its background, yet a chromosome gain or whole-genome duplication can also raise that gene's absolute dosage. Classification therefore depends on scale and reference rather than on a high target count alone.

Diagnostic: Does the target rise relative to appropriate neighboring and genome-wide references, or merely accompany aneuploidy or polyploidy?

T4: Natural genomic state versus artificial assay product. The same amplification vocabulary covers extra sequence copies present in cells and copies deliberately created in a reaction. That shared target-to-background invariant is useful, but it can cause an abundant assay product to be misread as evidence that the source genome was amplified.

Diagnostic: Were the extra copies already present in the sampled genome, or were they generated only by the measurement process?

T5: Adaptive advantage versus copy-number instability. Amplified loci can rapidly increase dosage under a pressure and later contract or segregate unevenly when that advantage disappears. Instability makes amplification responsive, while also limiting claims that a measured state is fixed, inherited, or representative of every cell.

Diagnostic: Across cells and time, is the gain stably maintained, selectively enriched, or declining after the relevant pressure changes?

T6: Phenotypic association versus causal contribution. An amplified gene may correlate with resistance, development, or disease because it contributes to the phenotype, because another feature of the amplified segment is causal, or because it is a passenger. Copy number establishes the structural state but cannot select among those causal accounts by itself.

Diagnostic: What independent comparison or intervention links the bounded copy gain, rather than a co-amplified feature, to the claimed phenotype?

T7: Measurement resolution versus normalization dependence. Sequencing, arrays, quantitative or digital PCR, hybridization, and cytogenetics expose different scales and physical arrangements of gain. Greater sensitivity can reveal mosaic or focal states, yet every estimate still depends on reference loci, ploidy, sample composition, mapping, and dynamic range.

Diagnostic: Does the chosen assay resolve the claimed structure, and would the copy-number conclusion survive plausible changes in its reference and sample-mixture assumptions?

T8: Gene Amplification autonomy versus reduction to Amplification (Amplification). The parent Prime carries the portable pattern of selectively increasing one component relative to a background. Every Gene Amplification is a strict kind of Amplification because a bounded gene or locus gains copies relative to its genomic or reaction reference. The child remains an in-situ genetic specialization because it fixes a nucleic-acid target, physical copy product, calibrated copy-number measurement, and boundaries against ploidy and expression; treating it as wholly autonomous hides the general increase pattern.

Diagnostic: Does the case preserve a bounded sequence and molecular copy-number relation, or only instantiate Amplification in the broader sense?

Structural–Framed Character¶

Gene Amplification is mixed-structural on the structural–framed spectrum because selective copy gain can be a natural genomic process independent of observers, while its identity is fixed by molecular carriers, target-to-background comparison, and a deliberate separation between genomic state and assay-produced copies. Its evaluative_weight is low: additional copies are not inherently adaptive, pathological, useful, or causal, and those interpretations require separate evidence. It is only partly human_practice_bound: natural developmental, selected, or pathological gains persist without measurement, whereas laboratory amplification and every reported copy-number estimate depend on designed methods and references. Its institutional_origin is similarly divided: the physical copies are not created by taxonomy, but genetics and molecular-diagnostic practice establish the gene, locus, amplicon, ploidy, and assay-state boundaries under which the name is applied. Its vocab_travels poorly outside molecular biology because gene, bounded locus, DNA or RNA copy, chromosome, amplicon, and copy-number assay retain typed biological referents. Under import_vs_recognize, different organisms, cell states, or laboratory methods can literally preserve the target-to-background copy-gain relation, while calling a larger signal or repeated message Gene Amplification would import molecular language by analogy.

The smallest positively reviewed portable skeleton is Amplification: a bounded input or component increases relative to a background through a resource-supported operation within a stated regime. The cross-domain reach of that selective-increase relation belongs to the Amplification Prime. Gene Amplification remains home-bound by a nucleic-acid target, genomic or reaction reference, physical sequence copies, copy-generating route, and boundaries against proportional chromosome or genome gain, expression change, and measurement-created product. Removing those molecular conditions leaves Amplification; removing the relative copy gain leaves replication, expression, or assay signal without the named identity.

Its character: mixed-structural because observer-independent copy-number change provides the structural pull, while molecular-genetic typing and assay-versus-genome interpretation impose the decisive frame.

Structural Core vs. Domain Accent¶

This decomposition explains why Gene Amplification is a domain-specific abstraction rather than a Prime.

What is skeletal (could lift toward a cross-domain prime). The carrier contains a bounded target distinguished from a broader background. A copy-generating process increases the target's representation relative to that background; the invariant is target identity under gain, and recognition fails when the observed increase is proportional across the whole carrier or exists only in an unrelated output measure. This realizes Amplification: a controlling target produces a magnified output through separately supplied resources within a bounded operating regime, while Amplification remains complete without genetic material or copy-number semantics.

What is domain-bound. The target is a gene or delimited DNA or RNA region, the background is a genomic or molecular reference, and the result is additional sequence copies produced in a stated natural or artificial context. Genomic scale, ploidy, sample mixture, assay range, and the distinction between copies already present in a source and copies created during an assay are constitutive to interpretation; expression and phenotype remain separate consequences. Substitute a generic signal for the sequence target, count whole-genome increase as selective gain, or infer genomic state from assay product alone, and the label Gene Amplification no longer applies.

Why this does not clear the prime bar. The complete bounded-sequence, target-to-reference copy-gain, genomic-scale, and assay-state signature does not recur literally across at least three unrelated domains with the same vocabulary, diagnostics, and intervention semantics. Knowledge Transfer assigns broader reach to Amplification; larger signals in electronics, communication, or social diffusion instantiate that parent or support analogy rather than Gene Amplification. Removing the molecular-genetic accent leaves selective amplification but not the named biological or assay identity, while removing the relative copy-generating structure leaves genes, expression changes, chromosome-wide dosage, or measurement output without the candidate-level abstraction.

This entry is a kind of Amplification.

Instantiates — Amplification (Amplification). The bounded sequence target or template is the controlling input, the added DNA or RNA copies are the enlarged output, and replication, recombination, rearrangement, or assay chemistry supplies the copy-generating operation and material resources. Sequence identity and target boundaries are preserved while the target-to-background copy ratio increases. The operating regime is bounded by genomic context or assay range, and saturation, instability, sample mixture, and normalization can limit what the gain means. If the target does not gain copies, or if it rises only because the whole genome or chromosome rises proportionally, the Gene Amplification identity and this Amplification mapping both collapse. The parent remains broader because it does not require a nucleic-acid target, copy-number reference, genomic structure, or molecular assay.

Relationships to Other Abstractions¶

Current abstraction Gene Amplification Domain-specific

Parents (1) — more general patterns this builds on

Gene Amplification is a kind of Amplification Prime

The bounded sequence target or template is the controlling input, the added DNA or RNA copies are the enlarged output, and replication, recombination, rearrangement, or assay chemistry supplies the copy-generating operation and material resources.

Hierarchy paths (3) — routes to 3 parentless roots

Gene Amplification → Amplification → Founder Effect → Path Dependence → Dependency

Show alternative paths (2)

Neighborhood in Abstraction Space¶

Gene Amplification sits in a sparse region of the domain-specific corpus (84^th percentile for distinctiveness): few abstractions share its structure, so a faithful description tends to retrieve it precisely.

Family — Unclustered & Miscellaneous (2551 abstractions)

Nearest neighbors

Computed from structural-signature embeddings · 2026-10-08

Not to Be Confused With¶

DNA replication. DNA replication is the molecular copying process that reproduces DNA, commonly across an entire genome before division; it can supply a copy-generating route, whereas gene amplification is the selective increase of a bounded gene or region relative to genomic background. Tell: Did the target gain copies disproportionately to reference loci, or was the surrounding genome copied in the same proportion?
Gene duplication. Gene duplication is the creation and evolutionary retention of an additional gene copy, which may later diverge in sequence, regulation, or function; it overlaps with amplification but does not by itself denote a multi-copy, potentially unstable target-to-background gain. Tell: Is the claim about a discrete additional paralog and its history, or about elevated copy number of a bounded target relative to its current genomic background?
Copy-number variation. Copy-number variation is the broader descriptive class of genomic gains and losses across multiple sizes and population frequencies; gene amplification is the gain-focused case in which a selected locus or region is represented in extra copies. Tell: Does the observation establish a target-specific copy gain, or only that copy number differs—including possible loss—within a broader variable region?
Aneuploidy and polyploidy. Aneuploidy changes the number of particular chromosomes, while polyploidy multiplies complete chromosome sets; both can raise gene dosage as part of a larger-scale proportional change rather than a focal amplification. Tell: Do reference loci across a chromosome or genome rise with the target, or is the target region selectively overrepresented?
Gene overexpression. Gene overexpression is increased RNA or protein output and can occur with or without extra genomic copies; it is a possible downstream consequence, not the copy-number identity. Tell: Is the evidence a calibrated DNA copy-number gain relative to reference loci, or only increased transcript, protein, or phenotype?
PCR amplification. PCR amplification is an artificial assay branch of Gene Amplification: it creates extra copies of a bounded target within a reaction rather than establishing that the source genome already carried a copy-number gain. Tell: Is the claim about target copies generated by the assay, or extra copies already present in the source genome before analysis?
Amplicon. An amplicon is the bounded nucleic-acid product or amplified segment produced by an amplification event; in an assay it is a product molecule, while in genomics it can denote the amplified region. Tell: Is the term naming the product or segment being counted, or the biological or artificial process that increased its copy number?

References¶

[1] Gene Amplification - MeSH - NCBI registry ↩

[2] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[3] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[4] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[5] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[6] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[7] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[8] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[9] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[10] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩

[11] Unverified encyclopedia synthesis; claim-specific authoritative support was not established in this verification pass. ↩